Longer colonoscopy withdrawal times associated with lower cancer rate
the ONA take:
Colonoscopy withdrawal times of 6 minutes or more are associated with lower colon cancer rates, according to research by a Veterans Affairs team.
The link between colonoscopy withdrawal time and patient outcomes is already known; this study provides strong evidence to support clinical guidelines regarding colonoscopy withdrawal times. Current guidelines recommend a withdrawal time of 6 minutes or more.
In this study, data on colonoscopies performed over 6 years by 51 gastroenterologists in a large community practice were evaluated. The average withdrawal time for the practice was 8.6 minutes; however, approximately 10% of the doctors had individual averages of less than 6 minutes.
The researchers then reviewed the state’s cancer registry for colorectal cancer cases among patients who had been screened at the practice during the study period, including cancers that occurred within 5 years of the last screening.
Referred to as interval cancers, these cancers are assumed to have developed from polyps that were either not detected during the colonoscopy, or not fully removed.
The American College of Gastroenterology acknowledges that some colons can be effectively examined in less than 6 minutes, but these findings show longer colonoscopy withdrawal times correlate with lower risk for interval cancer. The researchers report that further research is needed on quality measures for this screening procedure.
Colonoscopy withdrawal times of 6 minutes or more are associated with lower colon cancer rates.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|